Andy is a chemist by training with more than 12 years’ experience in multiple areas of chemistry, biotechnology and diagnostics. He completed his undergraduate and postgraduate degrees at the University of Bristol. After two postdoctoral positions, he joined a London-based start-up – Econic Technologies – focused on the commercialisation of a CO2/epoxide polymerisation technology before moving to Kingston University London to begin his independent academic career, where he was appointed Senior Lecturer. His research at Kingston was focused on creation of supramolecular sensors for small molecules.

In 2017, Andy returned to Bristol to join Ziylo as CSO, where he led the company’s scientific team during its transition from the university to private laboratories (now at Science Creates). Later that year, he was appointed as a director and ultimately played a critical role in guiding the company towards its landmark acquisition by Novo Nordisk in August 2018. During the acquisition, Andy co-founded Carbometrics to commercialise the same Glucose Binding Molecule technology for glucose sensing applications, under license from Novo Nordisk, and closed a ca. £650K seed investment round upon incorporation.

In 2020, Andy was awarded the Royal Society of Chemistry ‘Rising Star in Industry’ award for his efforts so far, and in 2021 he led the first institutional fundraising, securing £2.1M in an oversubscribed bridge-to-series A round. In August 2022, Andy led and closed a major Series A investment into Carbometrics by a medical device company that has set the course for the company to commercialise its revolutionary CGM technology. He recently completed his MBA with the Biotechnology Business Institute and also serves as an advisor and NED to several other small life science companies.